Healthcare Industry News: dialysis
News Release - June 20, 2011
Boston Scientific Announces Global Launch of Mustang PTA Balloon CatheterLow-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures
NATICK, Mass., June 20, 2011 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE:BSX ) today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures. The Company plans to launch the product immediately in the U.S., Europe and other international markets.
Boston Scientific developed the Mustang PTA Balloon Catheter to meet physician needs for a low-profile, high-pressure balloon catheter in a wide range of sizes. It is the first to use Boston Scientific's NyBax™ Balloon Material, a proprietary co-extrusion of nylon and Pebax® polymers engineered to provide high-pressure, non-compliant dilatation in a low-profile balloon. The Mustang Balloon Catheter offers excellent rated burst pressure (up to 24 atmospheres) and is the only 7 x 200 mm balloon compatible with a 5 French introducer sheath. Available in 203 sizes, it provides the broadest matrix of any available peripheral balloon.
"The Mustang Balloon Catheter offers a low tip profile and excellent deliverability to accommodate workhorse and complex lesions," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit. "Its versatility and extensive size matrix allow physicians to address nearly every peripheral need, ranging from treating blockages in femoral arteries to dialysis fistulae. The Mustang Balloon Catheter demonstrates Boston Scientific's commitment to continuing its legacy as a pioneer and global leader in peripheral balloon angioplasty."
An estimated 8 to 10 million patients in the United States alone suffer from peripheral artery disease (PAD), which is characterized by blockages in vessels of the peripheral vasculature and is associated with high rates of morbidity. PTA balloon catheters are used in peripheral angioplasty and stenting procedures to open blocked arteries.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, the market for peripheral artery disease treatment, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.